A Lesion based and Sub-regional Comparison of FDG PET/CT and MDP Bone Scintigraphy in Detection of Bone Metastasis in Breast Cancer

2017 ◽  
Vol 13 (4) ◽  
Author(s):  
Selin S. Demir ◽  
Gul E. Aktas ◽  
Fusun U. Yenici
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Bone Scintigraphy ◽  
Fdg Pet ◽  
Regional Comparison ◽  
Pet Ct ◽  
Fdg Pet Ct

Comparison of (18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma

2013 ◽  
Vol 42 (12) ◽  
pp. 1673-1681 ◽  
Author(s):  
Byung Hyun Byun ◽  
Chang-Bae Kong ◽  
Ilhan Lim ◽  
Byung Il Kim ◽  
Chang Woon Choi ◽  
...  
Keyword(s):  
Bone Metastasis ◽  
Bone Scintigraphy ◽  
Fdg Pet ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Bone Marrow Metastasis Is an Early Stage of Bone Metastasis in Breast Cancer Detected Clinically by F18-FDG-PET/CT Imaging

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Kusai M. Al-Muqbel
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Bone Metastasis ◽  
Bone Metastases ◽  
Fdg Pet ◽  
Early Stage ◽  
Ct Imaging ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Objective. To determine the value of 18F-FDG PET/CT in detection of bone marrow (BM) metastasis in breast cancer which is considered an early stage of bone metastasis. Patients and Methods. Retrospectively, breast cancer patients with bone metastasis were included. BM metastasis was considered if the lesion was PET positive/CT occult while bone metastasis was considered if the lesion was PET positive/ CT positive. BM metastases were observed sequentially on F18-FDG PET/CT. Results. We included 35 patients. Eighteen patients (51%) had BM metastases in addition to other bone metastases. BM metastases comprised 24% of all lesions. Posttreatment scan was performed on 26/35 patients. Twenty-three percent of BM metastases had resolved completely without causing bone destruction after treatment. Sixty-five percent of BM metastases had converted into bone metastases after treatment. Twelve percent of BM metastases had persisted after treatment. Conclusion. This retrospective study showed clinically by 18F-FDG PET/CT imaging that BM metastasis is an early stage of bone metastasis in breast cancer. Interestingly, 18F-FDG-PET/CT showed that early eradication of individual BM metastasis by systemic treatment precluded development of bone metastasis. However, more research is needed to study the impact of an early diagnosis of BM metastases on treatment outcome.

scholarly journals Diagnostic Value of18F-FDG PET/CT in Comparison to Bone Scintigraphy, CT and18F-FDG PET for the Detection of Bone Metastasis

2013 ◽  
Vol 14 (6) ◽  
pp. 3647-3652 ◽  
Author(s):  
Ning-Bo Liu ◽  
Lei Zhu ◽  
Ming-Huan Li ◽  
Xiao-Rong Sun ◽  
Man Hu ◽  
...  
Keyword(s):  
Bone Metastasis ◽  
Bone Scintigraphy ◽  
Fdg Pet ◽  
Diagnostic Value ◽  
Pet Ct ◽  
Fdg Pet Ct

Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer

2011 ◽  
Vol 52 (9) ◽  
pp. 1009-1014 ◽  
Author(s):  
Steffen Hahn ◽  
Till Heusner ◽  
Sherko Kümmel ◽  
Angelika Köninger ◽  
James Nagarajah ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Bone Scintigraphy ◽  
Fdg Pet ◽  
Whole Body ◽  
Reference Standard ◽  
Breast Cancer Patients ◽  
Pet Ct ◽  
Fdg Pet Ct

Background Bone scintigraphy is the standard procedure for the detection of bone metastases in breast cancer patients. FDG-PET/CT has been reported to be a sensitive tool for tumor staging in different malignant diseases. However, its accuracy for the detection of bone metastases has not been compared to bone scintigraphy. Purpose To compare whole-body FDG-PET/CT and bone scintigraphy for the detection of bone metastases on a lesion basis in breast cancer patients. Material and Methods Twenty-nine consecutive women (mean age 58 years, range 35-78 years) with histologically proven breast cancer were assessed with bone scintigraphy and whole-body FDG-PET/CT. Twenty-one patients (72%) were suffering from primary breast cancer and eight patients (28%) were in aftercare with a history of advanced breast cancer. Both imaging procedures were assessed for bone metastases by a radiologist and a nuclear medicine physician. Concordant readings between bone scintigraphy and FDG-PET/CT were taken as true. Discordant readings were verified with additional MRI imaging in all patients and follow-up studies in most patients. Results A total of 132 lesions were detected on bone scintigraphy, FDG-PET/CT or both. According to the reference standard, 70/132 lesions (53%) were bone metastases, 59/132 lesions (45%) were benign, and three lesions (2%) remained unclear. The sensitivity of bone scintigraphy was 76% (53/70) compared to 96% (67/70) for FDG-PET/CT. The specificity of bone scintigraphy and FDG-PET/CT was 95% (56/59) and 92% (54/59), respectively. According to the reference standard bone metastases were present in eight out of the 29 patients (28%), whereas 20 patients (69%) were free of bone metastases. One (3%) patient had inconclusive readings on both modalities as well as on MRI and follow-up studies. Bone scintigraphy and FDG-PET/CT correctly identified seven out of eight patients with bone metastases and 20 out of 20 patients free of metastases. Conclusion On a lesion-basis whole-body FDG-PET/CT is more sensitive and equally specific for the detection of bone metastases compared with bone scintigraphy.

scholarly journals Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis

Medicine ◽  
2017 ◽  
Vol 96 (50) ◽  
pp. e8985 ◽  
Author(s):  
Soyeon Park ◽  
Joon-Kee Yoon ◽  
Su Jin Lee ◽  
Seok Yun Kang ◽  
Hyunee Yim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Bone Scintigraphy ◽  
Fdg Pet ◽  
Breast Cancer Patients ◽  
Pet Ct ◽  
Prognostic Utility ◽  
Fdg Pet Ct

scholarly journals Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer

Diagnostics ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 1021
Author(s):  
Jorun Holm ◽  
Ziba Ahangarani Farahani ◽  
Oke Gerke ◽  
Christina Baun ◽  
Kirsten Falch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Scintigraphy ◽  
Fdg Pet ◽  
Recurrent Breast Cancer ◽  
Distant Recurrence ◽  
Interrater Agreement ◽  
Whole Body ◽  
Breast Cancer Patients ◽  
Pet Ct ◽  
Fdg Pet Ct

The purpose was to investigate the interrater agreement of FDG-PET/CT and bone scintigraphy for diagnosing bone recurrence in breast cancer patients. A total of 100 women with suspected recurrence of breast cancer underwent planar whole-body bone scintigraphy with [99mTc]DPD and FDG-PET/CT. Scans were evaluated independently by experienced nuclear medicine physicians and the results for one modality were blinded to the other. Images were visually interpreted using a 4-point assessment scale (0 = no metastases, 1 = probably no metastases, 2 = probably metastases, 3 = definite metastases). Out of 100 women, 22 (22%) were verified with distant recurrence, 18 of these had bone involvement. The proportions of agreement between readers were 93% (86.3–96.6) for bone recurrence with FDG-PET/CT and 47% (37.5–56.7) for bone recurrence with planar bone scintigraphy. The strengths of agreement between readers for diagnosing bone recurrence was ‘almost perfect’ with FDG-PET/CT and was ‘fair’ with planar bone scintigraphy according to Cohen’s kappa value of 0.82 (0.70–0.95) and 0.28 (0.18–0.39), respectively. Interrater agreement yielded improved reproducibility with FDG-PET/CT versus with bone scintigraphy when diagnosing recurrence with bone metastasis in this patient cohort.

Sign in / Sign up

Export Citation Format

Share Document